A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (NCT06256588)
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Dostarlimab as Sequential Therapy After Chemoradiation in Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
🩺 Plain-English Summary (8th-Grade Level)
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Jonesboro, Arkansas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (277 Sites)
Showing the first 25 of 277 sites.
- GSK Investigational Site — Jonesboro, Arkansas
- GSK Investigational Site — Los Angeles, California
- GSK Investigational Site — Solvang, California
- GSK Investigational Site — Stockton, California
- GSK Investigational Site — Torrance, California
- GSK Investigational Site — Farmington, Connecticut
- GSK Investigational Site — New Haven, Connecticut
- GSK Investigational Site — Washington D.C., District of Columbia
- GSK Investigational Site — St. Petersburg, Florida
- GSK Investigational Site — Tamarac, Florida
- GSK Investigational Site — Atlanta, Georgia
- GSK Investigational Site — Fort Wayne, Indiana
- GSK Investigational Site — Iowa City, Iowa
- GSK Investigational Site — Lexington, Kentucky
- GSK Investigational Site — Columbia, Maryland
- GSK Investigational Site — Worcester, Massachusetts
- GSK Investigational Site — St Louis, Missouri
- GSK Investigational Site — Omaha, Nebraska
- GSK Investigational Site — New York, New York
- GSK Investigational Site — The Bronx, New York
- GSK Investigational Site — Canton, Ohio
- GSK Investigational Site — Cincinnati, Ohio
- GSK Investigational Site — Tulsa, Oklahoma
- GSK Investigational Site — Philadelphia, Pennsylvania
- GSK Investigational Site — Pittsburgh, Pennsylvania
📞 Contact the Study Coordinator
Phone: (877) 379-3718
Email: GSKClinicalSupportHD@gsk.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Neoplasms, Head and Neck
Explore by condition: All Neoplasms, Head and Neck clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.